Background/Aims: To evaluate the clinicopathologic aspects of small cell neuroendocrine carcinoma of the uterine cervix (SCNEC). Methods: A retrospective review of 40 patients with SCNEC in 3 hospitals from 2009 to 2015 was conducted to assess the survival rates and examine the associations between clinicopathological variables and overall survival (OS). A meta-analysis of 22 studies containing 1901 patients was also conducted to further confirm the results. Results: In the clinical group of 40 patients, the 5-year OS rate was 20%. Advanced International Federation of Gynecology and Obstetrics (FIGO) stage and radiation therapy (RT) were associated with poor survival. However, radical surgery was associated with prolonged survival. In the meta-analysis of 1901 patients, the 2-year disease-free survival (DFS) rate, 5-year DFS rate, 2-year OS rate, 3-year OS rate and 5-year OS rate of SCNEC were 48%, 35%, 62%, 35%, and 35% respectively. Advanced FIGO stage, larger tumor size, lymph node metastasis (LNM) (+), lymphovascular space involvement (LVSI) (+), parametrial involvement (PI) (+), depth of stromal invasion (DSI) > 2/3, and RT were associated with poor survival. However, a chemotherapy regimen similar to that for small cell lung cancer was associated
Introduction
Small cell neuroendocrine carcinoma of the uterine cervix (SCNEC) is a rare disease that accounts for less than 5% of all uterine cervical carcinomas [1] . Compared with squamous cell carcinoma (SCC) or adenocarcinoma (ADC) of the cervix, SCNEC is more likely to be an aggressive type that develops distant metastases, even in its early stages [2] . However, past studies have shown disagreement in the 5-year overall survival (OS) rate of SCNEC. The lowest rate was reported by Li et al. as 4% [3] and the highest was reported by Chen et al. as 51% [4] .
Because of the low incidence of SCNEC, previous studies were mostly clinical case reports or case series, making it difficult to draw conclusions on overall management [5] . In addition to FIGO stage [6, 7] , several potential prognostic factors [2, [8] [9] [10] [11] [12] [13] [14] including age, tumor size, lymphovascular space involvement (LVSI), lymph node metastasis (LNM), depth of stromal invasion (DSI), parametrial involvement (PI), and treatment modality have been shown to influence survival, though not in all studies. For example, Lee et al. [15] reported that in patients with stage IB-IIA SCNEC, neoadjuvant chemotherapy tended to improve 5-year survival. However, the number of patients was limited. Because there are no published guidelines for the prognosis and treatment of SCNEC to date, knowledge regarding the treatment regimens and factors for survival is still fragmentary.
Knowledge of potential prognostic factors is important for the optimal selection of treatment modalities, monitoring of treatment response, and planning of follow-up. Although there is a large body of literature on prognostic factors for cervical cancer, we are unaware of studies examining the magnitude of prognostic factors according to histological type among patients with SCNEC, SCC, or ADC. Therefore, the aim of this cohort study was to generate an assessment of the survival rates, clinicopathological variables and treatment strategies associated with prognosis of SCNEC patients from 3 hospitals in China over a 6-year period and from the PUBMED database over a 22-year period.
Materials and Methods

Patients
Forty patients with SCNEC from 3 hospitals (Nanfang Hospital, Southern Medical University; Tongji Hospital, Huazhong University of Science and Technology; Xiangyang central hospital, Hubei University of Arts and Science) who were diagnosed from January 2009 to October 2015 were enrolled in this study. All 40 patients were definitively diagnosed by two pathologists after a second examination of specimen slides. The retrospective part of this study was approved by the Ethics Committees of Nanfang Hospital, Tongji Hospital, and Xiangyang Central Hospital respectively. Because of the retrospective study design, informed consent could not be obtained from the patients. Instead of obtaining informed consent from each patient, we posted a notice about the study design and contact information in a public location.
Search strategy
We searched the PUBMED database from 1995 to 2017 for articles evaluating the effect of SCNEC on any prognostic index of human cancers, including survival, stage at diagnosis, treatment choice, and other factors, such as age, tumor histology, tumor size, FIGO stage, PI, LNM, LVSI, and DSI. Our overall search strategy included terms for cervical cancer ("cervix", "small cell neuroendocrine"), cancer (eg, "carcinoma", "malignant neoplasm"), and prognosis (eg, "mortality", "overall survival rate") and was limited to articles in the English or Chinese language and human studies. We also searched references of included articles. 
Study selection
Inclusion and exclusion criteria were as follows: (i) studies with a retrospective design or case series; (ii) studies where the histologic tumor type was SCNEC; (iii) studies that provide data on age, tumor FIGO stage, tumor histology, LNM, tumor size, LVSI, PI, SM, DSI, radiation therapy, chemotherapy, chemotherapy regimen, survival rates, hazard ratio (HR), and 95% confidence interval (CI) or sufficient survival data; (iv) studies that used similar research methods; (v) studies with 15 or more patients and published in English or Chinese language; and (vi) studies published between January 1995 and August 2017. Regarding exclusion criteria, case series with a sample size of less than 15 patients were excluded and studies published before 1995 were excluded.
Two investigators (Xu Fan and Ma Jing) extracted the data from the studies. All data were verified by internal consistency, and disagreements were resolved by discussion between the two investigators. The meta-analysis part of the study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University.
Data extraction
A data extraction form was used to record all the required data from each study. This form included sample size, study region, survival rates, as well as the HRs of prognostic factors such as age, FIGO stage, tumor histology, LNM, tumor size, LVSI, PI, SM, DSI, and treatment strategies.
Statistical analysis
OS was calculated from the time of initial diagnosis until death; patients who were alive at the last follow-up were censored. Prognostic factors affecting OS were estimated using the Cox proportional hazards model, and HRs of the risk factor were calculated using IBM SPSS version 19.0. All the tests were two-sided, and P<0.05 was considered statistically significant. The meta-analysis was carried out using STATA version 12.0. The effect of risk factors on prognosis was presented as HR with 95% CI. Overall pooled HR was estimated by calculating the weighted average of the study-specific logarithmically transformed (log) HR and its standard error from the reported results or calculating them directly using the method reported by Tierney et al. [16] . The chi-squared test for homogeneity was performed, and heterogeneity was considered significant when I 2 was over 50% or P<0.1. A random effects model was used for meta-analysis. Publication bias was assessed graphically using funnel plots and regression tests. P<0.05 was considered statistically significant.
Results
Survival rates and prognostic factors of SCNEC in the clinical group
Demographic characteristics of the patients are shown in Table 1 . Of the 40 patients, 80% had a pure histological type composed of SCNEC, and 8 patients (20%) had a mixed pattern associated with SCC or ADC in addition to the SCNEC component. The median survival time was 19 (ranging from 3-71) months, and the estimated 5-year OS rate for the clinical group was 20% (Fig. 1A) . We assessed various clinicopathologic 
Meta-analysis of published studies
Survival rates and prognostic factors of SCNEC in the meta-analysis A total of 22 papers including 1901 patients were enrolled in the metaanalysis, and the main features of the eligible studies for aggregation are listed in Table 3 . The publication time period of the studies was between 1995 and 2017. The 22 studies originated from three regions: Asia (17), the United States (4), and other (1). We assessed OS rates, and disease-free survival (DFS) rates to present the valid estimation of survival in patients with SCNEC, and got the estimated pooled survival rates as follows ( Fig. 2 and 1B Table 4 , [35] 1998 Taiwan 40 SCNEC 1988-1996 NA Bermudez A [36] 2001 Argentina 20 NECC 1983-1999 NA Chan JK [7] 2003 USA 34 SCNEC 1979-2001 NA Viswanathan AN [17] 2004 
Sensitivity analysis
To assess the stability of each pooled result in our meta-analysis, we conducted a sensitivity analysis for each analysis by sequential omission of individual studies. There was no significant difference in the survival rates and prognostic factors.
Publication bias analysis
We used Beggar's and Egger's tests to examine potential publication bias among the studies. The two tests showed no evidence of statistical publication bias among the survival rates and prognostic factors.
Discussion
SCNEC survival rates
In recent decades, success has been achieved in the management of SCNEC. Nevertheless, SCNEC is still a malignant tumor with poor prognosis [4, [17] [18] [19] [20] . Our multicenter retrospective study revealed that the 5-year OS rate for the 40 patients was 20% (Fig. 1) , lower than the pooled 5-year OS rate of 37% in the meta-analysis (Fig. 2) . The most likely reason for this significant difference between the clinical group and meta-analysis was the low incidence of SCNEC and limited number of patients. Moreover, compared with that of SCNEC, the 5-year OS rates of SCC and ADC were 74.3% and 64.6%, respectively [21] , which suggested that SCNEC was more malignant than the common types of cervical cancer.
The survival information gained from the present analysis can also help in the longterm fellow up of patients with SCNEC. In the meta-analysis, estimation of the pooled 2-year OS rate, 3-year OS rate, and 5-year OS rate were 62%, 35%, and 35%, respectively. The results suggest that about 40% of SCNEC deaths occurred within the second year following diagnosis and another 30% took place during the third year. Furthermore, it could mean that we should pay more attention to patients with SCNEC during the second year and third year after treatment and try to find the reason for the sudden declines in OS rate in the second year.
Estimations of the pooled 2-year DFS rate and 5-year DFS rate were respectively 48% and 35% in the meta-analysis. The results illustrate that more than half of SCNEC patients suffered recurrence within the second year following diagnosis and another 10% of patients had disease progression between the second year and the fifth year. From these results, due to the aggressive nature of SCNEC [22] , distant micrometastasis must always be assumed to be present [23] . Hence, closer attention should be paid during the first 3 years after treatment.
Prognostic factors for SCNEC The effects of tumors on prognostic factors, either by direct tumor extension or by distant metastasis, is a major challenge. If the tumor extends rapidly, prognosis is poor, even after treatment. Clinicopathologic factors, including tumor size, LVSI, DSI, surgical margins, and PI are frequently used to evaluate the prognosis of cervical cancer in common histologic types such as SCC, ADC, and adenosquamous carcinoma [7, [23] [24] [25] [26] [27] [28] [29] . However, relevant factors for SCNEC remain controversial. Our findings among the clinical group of 40 patients showed that only advanced FIGO stage tended to be associated with poor survival. To further identify other potential prognostic factors for SCNEC, we conducted a meta-analysis to generate a reliable estimation of potential prognostic factors for SCNEC ( Based on the results of the retrospective study and meta-analysis, these factors, as in the case of common histologic types of cervical cancer, can also be used to evaluate the prognosis of SCNEC and contribute to the accurate assessment of the progress of the disease. Furthermore, treatment options should be chosen according to the prognostic factors. For example, the National Comprehensive Cancer Network (NCCN) guidelines recommend conservative treatment using conization for FIGO stage IA1 cervical cancer with LVSI (-). However, this option is not recommended for patients with the same stage but with LVSI (+) Fig. 2 . Meta-analysis of the 2-year disease-free survival (DFS) rate, 5-year DFS rate, 2-year overall survival (OS) rate, 3-year OS rate and 5-year OS rate of SCNEC. The pooled 5-year OS rate from 14 studies was 35%; the pooled 3-year OS rate from 4 studies was 35%; the pooled 2-year OS rate from 7 studies was 62%; the pooled 5-year DFS rate from 2 studies was 35%; the pooled 2-year DFS rate from 2 studies was 48%. Cellular Physiology and Biochemistry [30] . Patients with SCNEC who have advanced FIGO stage, larger tumor size, (+) LNM, (+) LVSI, DSI > 2/3, and/or PI (+) should be managed with an alternative treatment modality to avoid recurrence and disease progression in the future. Potential therapeutic approach for SCNEC Currently, there is still no consensus on which modality should be the first-line treatment for SCNEC [31] . On the one hand, because of the similar features, the treatment strategy for SCNEC is essentially extrapolated from that for SCLC. VAC (vincristine, adriamycin, and cyclophosphamide) or EP (etoposide and cisplatin) regimens have frequently been used for SCNEC [14, 32] . On the other hand, in China, radical surgery is the main treatment chosen by patients with SCNEC in early FIGO stages because of the recommendation of NCCN for the common types of cervical cancer [30] . As a result, SCNEC has always been treated with a combination of surgery, chemotherapy, and/or RT [33] . However, there is no consensus on the efficacy of treatment protocols.
The Society of Gynecologic Oncology (SGO) recommends that for cervical neuroendocrine tumors less than 4 cm, radical hysterectomy with lymphadenectomy should be performed, with the option of adjuvant chemotherapy [29, 34] . However, some studies have questioned the efficacy of radical surgery for this rare disease [4, 11] . Our findings in the clinical group suggest that radical surgery is associated with prolonged survival, and also support the SGO recommendation. As for chemotherapy, the conclusions of our meta-analysis demonstrate that chemotherapy regimens like VAC or PE, which are similar to those for SCLC, had a significantly favorable impact on survival. In contrast, RT was associated with poor survival in the clinical group of 40 patients and the meta-analysis of 1901 patients. The above discussion tentatively suggests that radical surgery combined with a chemotherapy regimen similar to one for SCLC (VAC or PE) may be a potential therapeutic approach for SCNEC. Although we are unable to accurately identify the treatment for SCNEC, our results provide a thorough description of the cohort to help determine the optimal treatment and we recommend that the final decision should be in accordance with the clinical impression.
Limitations
The present study had some limitations. First, the retrospective design and the lack of randomized prospective studies reduced the value of our conclusions. Future prospective studies are needed to determine the survival rates and prognostic factors more accurately. Second, the number of patients in the clinical group was small and it is hard to get a reliable estimation of survival rates and prognostic factors. As such, we performed a separate analysis comparing the results from our data of 40 patients with that of a meta-analysis, and this lends support to our results. Third, the potential for selection bias could not be completely eliminated as only English and Chinese literature was included in the meta-analysis. Moreover, we had to conduct a meta-analysis to identify the optimal potential therapeutic approach because of the limited data. It is hoped that more gynecological cancer centers will participate and cooperate in the search for more optimized and effective therapy regimens.
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